NL-OMON23085已完成不适用
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid?
Het Oogziekenhuis RotterdamRotterdams Oogheelkundig Instituut0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
Mulder VC, Kluft C, van Etten PG, La Heij EC, van Meurs JC. Higher vitreous concentrations of dabigatran after repeated oral administration. Acta Ophthalmol. 2017; 95(4): e345-e346.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age > 18 years
- •- Informed consent
排除标准
- •- Using other anticoagulants (e.g. acenocoumarol, heparin etc)
- •- Using medication that increases risk of GI bleeding (e.g. aspirin, NSAIDs, SSRIs, oral corticosteroids).
研究者
相似试验
进行中（未招募）
1 期
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve significant levels and thrombin inhibiting activity in the eye?Ocular accessibility of dabigatran in patients with retinal detachmentEUCTR2014-000388-41-NLThe Rotterdam Eye Hospital28
已完成
不适用
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid?10015917proliferative vitreoretinopathyNL-OMON40980Oogziekenhuis Rotterdam24
招募中
不适用
Pharmacokinetics and –dynamics of Dabigatran Etexilate and Rivaroxaban in patients requiring PArenteral Nutrition (the PDER PAN study)parenteral nutrition, thrombosis, pharmacokinetics, pharmacodynamics, anticoagulantNL-OMON26342Academic Medical Center, Amsterdam, The Netherlands6
已完成
1 期
Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy VolunteersHealthyNCT02044367Boehringer Ingelheim54
已完成
2 期
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of AgeVenous ThromboembolismNCT02223260Boehringer Ingelheim8